The emphasis in cancer drug development has shifted from cytotoxic, non-specific chemotherapies to molecularly targeted, rationally designed drugs promising greater efficacy and fewer side effects. Nevertheless, despite some successes drug development remains painfully slow. Here, the issues involved and suggest ways in which this process can be improved and expedited. Shift for integrated cancer research and biomarker-driven adaptive, hypothesis testing for clinical trials. The goal is the development of specific cancer medicines to treat the individual patient, with treatment selection being driven by a detailed understanding of the genetics and biology of the patient and their cancer.